Healthcare Professionals

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
Actualités

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Coming Up: A TIF Live Webinar on  »Heart Disease in Thalassaemia »
Actualités

Coming Up: A TIF Live Webinar on  »Heart Disease in Thalassaemia »

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
eThalED Webinar Series: Iron Monitoring in Thalassaemia
Education

eThalED Webinar Series: Iron Monitoring in Thalassaemia

TIF´s 5th consecutive webinar for Medical Specialists and Healthcare Professionals was conducted on 7 September 2020 and revolved around the topic of  »Iron Monitoring in Thalassaemia ». Dr Paul Telfer, Consultant…
eThalED Webinar Series: Blood Transfusion in Thalassaemia
Education

eThalED Webinar Series: Blood Transfusion in Thalassaemia

TIF´s 4th Webinar for Medical Specialists and Healthcare Professionals, organised as part of our eThalED Course, was successfully held on Monday, 31 August 2020. Prof. Constantina Politis, Associate Professor of…
IMPORTANT ANNOUNCEMENT: TIF’s Renzo Galanello Fellowship Programme 2020 To Be Rescheduled and Compressed
Actualités

IMPORTANT ANNOUNCEMENT: TIF’s Renzo Galanello Fellowship Programme 2020 To Be Rescheduled and Compressed

Due to some difficulties and restrictions encountered as a result of the COVID-19 pandemic, the Renzo Galanello Fellowship Programme 2020 will not be offered in its full length and as initially…
Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial
Actualités

Pfizer Has Reached Over 50% Enrollment for Coronavirus Vaccine Candidate Phase 3 Trial

One of the leading COVID-19 vaccine candidates currently in development is getting closer to a potential finish line. Pfizer said on Wednesday that the recruitment for the crucial U.S. phase 3 clinical…
Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early
Actualités

Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early

Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…
The eThalED Course Webinar Series Return With a New Session on Iron Monitoring in Thalassaemia
Actualités

The eThalED Course Webinar Series Return With a New Session on Iron Monitoring in Thalassaemia

TIF´s upcoming webinar on  »Iron Monitoring in Thalassaemia », specially designed and launched for medical specialists and healthcare professionals with a particular interest in the field of haemoglobin disorders and thalassaemia,…
eThalED Webinar Series: Liver Disease & Thalassaemia
Education

eThalED Webinar Series: Liver Disease & Thalassaemia

TIF’s 3rd webinar for Medical Specialists on ”Liver Disease & Thalassaemia”, organised in the context of our eThalED Course. Prof. Geoffrey Dusheiko, Emeritus Professor of Medicine & Consultant Hepatologist at…
 »Blood Transfusion in Thalassaemia »: Save the Date for the Next TIF Webinar for Medical Specialists
Actualités

 »Blood Transfusion in Thalassaemia »: Save the Date for the Next TIF Webinar for Medical Specialists

TIF´s brand new Webinar, entitled  »Blood Transfusion in Thalassaemia » and organised as part of the eThalED Course, will be held on Monday, 31 August 2020, 15:00-16:00 EEST / 13:00-14:00 BST.…
Bouton retour en haut de la page